On September 28, 2026, Daré Bioscience, Inc. received a notice from Nasdaq indicating its common stock had traded below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has been granted an initial 180-day compliance period ending March 29, 2027, to restore the closing bid price to at least $1.00 for ten consecutive business days. Failure to comply may result in further review and potential delisting, though Daré retains the option to effect a reverse stock split if necessary to meet listing standards. The company operates in the biotechnology industry, developing therapeutic treatments.
